Table 2.
Clinical Response of BCMA CAR T Cell Therapies in Multiple Myeloma.
| Drug | Company | Grade 3-4 TEAE | CRS | Response Rate | Survival (e.g. PFS, DOR, OS) |
|---|---|---|---|---|---|
| Idecabtagene vicleucel (ide-cel) (93) | Bristol Myers Squibb/bluebird bio | CRS 5%, Neurotoxicity 3%, | 84% | ORR: 73%; CR: 33% | median DOR: 10.7 m; median PFS: 8.8 m (95% CI, 5.6-11.6); OS 78% at 12 m (estimates) |
| Ciltacabtagene autoleucel (cilta-cel) (94) | Janssen | neutropenia (94.8%), anemia (68.0%), leukopenia (60.8%), thrombocytopenia (59.8%), and lymphopenia (49.5%) | 95% | ORR: 98%; ≥VGPR: 95%; sCR: 80.4% | median DOR: 21.8 m – NE; 2-yr PFS: 60.5% (95% CI, 22.8 m – NE) |
| P-BCMA-101 (95) | Poseida Therapeutics | neutropenia 79%, thrombocytopenia 30%, anemia 30% | 17% | ORR: 57% | Responses ongoing |
| bb21217 (96) | Bristol Myers Squibb/bluebird bio | CRS 1%, neurotoxicity 4% | 75% | ORR: 69%; ≥VGPR: 58%; sCR/CR: 28% | estimated median DOR: 27.2 m |
| CT053 (97) | CARsgen Therapeutics | neutropenia 100%, leukopenia 100%, thrombocytopenia 36% | 86% | ORR: 87.5%; CR: 79% | median DOR: 21.8 m |
| CT103A (98) | Nanjing IASO Biotherapeutics | leukopenia 100%, neutropenia 100%, lymphopenia 100%, anemia 89%, thrombocytopenia 94% | 94% | ORR: 100%; CR/sCR: 72% | 1-yr PFS: 58.3% |
| ALLO-715 (99) | Allogene Therapeutics | CRS 2%, infections 13% | 52% | ORR: 62%; VGPR: 39% | median DOR: 8.3 m (95% CI: 1.5 – not reached) |
TEAE, treatment-related adverse events; CRS, cytokine release syndrome; ORR, overall response rate; CR, complete response; sCR, stringent complete response; VGPR, very good partial response; PFS, progression-free survival; DOR, duration of response; OS, overall survival; m, month; yr, year; NE, not estimable.